Last reviewed 2026-04-20 · How we verify

Tobanum (CLORANOLOL)

Phase 2 active Small molecule

Tobanum (generic name: CLORANOLOL) is a cloranolol drug. It is currently in Phase 2 development.

Tobanum works by interacting with a specific target in the body to produce a therapeutic effect.

Tobanum (CLORANOLOL) is a small molecule drug in the cloranolol class, but its target and exact mechanism of action are unknown. It is not clear if it is FDA-approved or commercially available. There is limited information available on its pharmacokinetic properties, such as half-life and bioavailability. Tobanum is not listed as an off-patent or generic medication. Further research is needed to understand its clinical applications and safety profile.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CLORANOLOL
Drug class	cloranolol
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Unfortunately, the exact mechanism of action of Tobanum is not well understood, but it is thought to involve the modulation of a particular cellular pathway to produce a desired outcome.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Tobanum CI brief — competitive landscape report
Tobanum updates RSS · CI watch RSS

Frequently asked questions about Tobanum

What is Tobanum?

Tobanum (CLORANOLOL) is a cloranolol drug.

How does Tobanum work?

Tobanum works by interacting with a specific target in the body to produce a therapeutic effect.

What is the generic name of Tobanum?

CLORANOLOL is the generic (nonproprietary) name of Tobanum.

What drug class is Tobanum in?

Tobanum belongs to the cloranolol class. See all cloranolol drugs at /class/cloranolol.

What development phase is Tobanum in?

Tobanum is in Phase 2.

Drug class: All cloranolol drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing